Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology, Hematological Malignancy, and Immune Disorder Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ELF2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ELF2 Recombinant Protein (Wild-Type, Full-Length & ETS Domain). High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified, HEK293 expressed. Ideal for SPR, PROTAC ternary complex, AlphaScreen/TR-FRET, and EMSA. | View ELF2 Products |
| Mutant Panel | ELF2 Mutant Variants (R281W, E235K). For resistance profiling, selectivity assays, and target engagement confirmation. Sequence Verified. | View ELF2 Products |
| Gene Delivery | ELF2 Promise-ORF / Lentivirus. Full-length ORF for stable reporter cell lines. CMV/EF1a promoter options, puromycin selection. | View ELF2 Products |
| Benchmark Ab | Anti-ELF2 Monoclonal Antibody (ChIP-Grade). Recombinant rabbit mAb with epitope mapped to non-conserved N-terminal region to minimize cross-reactivity. Suitable for western blot, pull-down, and ChIP. | View ELF2 Products |
| Validator | ELF2 siRNA Set. For transcriptional knockdown verification, functional validation, and specificity control in EMSA/ChIP/qPCR workflows. | View ELF2 Products |
| Related Target A | ERG. Crucial ETS family member for selectivity profiling and off-target screening. | View ERG Products |
| Related Target B | RUNX1. Interacting transcriptional co-factor essential for hematopoiesis modeling and myeloid differentiation studies. | View RUNX1 Products |
| Related Target C | SPI1 (PU.1). ETS family heterodimerization partner, critical for hematopoietic regulation and PPI assay controls. | View SPI1 Products |
| Related Target D | FLI1. ETS family member for selectivity counter-screening, especially in megakaryocyte and B-cell development. | View FLI1 Products |
| Related Target E | ELF1. Essential for ETS-family selectivity counter-screening and off-target assessment. | View ELF1 Products |
| Related Target F | ELF4 (MEF). Paralog with highly conserved DNA-binding domain; required for antibody cross-reactivity profiling. | View ELF4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| PROTAC Ternary Complex Validation | High-purity (>95%) recombinant ELF2 protein with native folding, verified by mass spec, for ternary complex formation assays (AlphaLISA, BLI). |
| ETS Family Cross-Reactivity & Selectivity | Homolog panel proteins (ERG, FLI1, SPI1, ELF1, ELF4) strictly sequence-verified by mass spec. Available for counter-screening. |
| Intracellular Target Validation & Cell-Based Reporter Assays | Premade ELF2 Lentivirus (Puromycin selection) for rapid generation of stable luciferase-reporter or ChIP-ready cell lines. |
| Lack of Reliable Cellular Controls | Lentivirus-ready ORFs for establishing consistent, physiologically relevant overexpression models. |
| Lack of Specific Detection Reagents | Anti-ELF2 Recombinant Rabbit mAb, epitope mapped to non-conserved N-terminal region to minimize cross-reactivity with other ETS factors. |
| Allosteric Pocket Identification | Multiple domain constructs (DBD, TAD, Pointed domain) for fragment-based screening and structural studies. |
| False Positives in DNA Binding Assays | Validated siRNA Set included for knockdown-specificity confirmation in EMSA / ChIP / qPCR workflows. |
| Mutant vs Wild-Type Selectivity | ELF2 mutant variants (R281W, E235K) for differentiating on-target effects from resistance mechanisms. |
Live ELF2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for targeting transcription factors like ELF2 (E74-like factor 2) is intensifying. As first-generation small molecules and chemical probes enter lead optimization, the field is shifting from broad epigenetic modulators to specific transcription factor inhibitors, with major players focusing on protein-protein interaction disruptors, allosteric modulators, and targeted degradation strategies (PROTACs, Molecular Glues) to overcome the historical "undruggability" of ETS factors. Early discovery programs are also exploring peptide disruptors of ELF2–protein interactions and RNA interference (ASOs/siRNA). While direct clinical-stage compounds remain limited, ELF2 has gained traction as a modulator of immune cell differentiation and survival, especially in hematological malignancies such as AML, MDS, B-cell malignancies, and autoimmune diseases. The next wave of R&D is expected to emphasize combination strategies with B-cell and myeloid lineage regulators (e.g., BTK, BCL2 inhibitors) and rigorous selectivity profiling against the ETS family.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI / Allosteric) | Emerging biotech, Academic consortia | AML, MDS, Refractory Cancers | Purified full-length ELF2 & domain constructs for AlphaScreen/TR-FRET, SPR, and TSA. |
| Targeted Degradation (PROTACs) | Early-stage biotechs, TPD-focused companies | Hematological Malignancies, Relapsed/Refractory Leukemia | High-purity recombinant ELF2 for ternary complex formation (AlphaLISA, BLI). |
| Molecular Glue | Early discovery programs (undisclosed) | Hematologic cancers | Mutant vs WT selectivity assays using R281W variants for target engagement. |
| RNAi / ASOs | Oligonucleotide developers | Solid Tumors, Immune Disorders | Validated siRNA set; gene delivery lentivirus for cellular knockdown verification. |
| Peptide / Protein Interaction Inhibitors | Early-stage biotech & academic consortia | B-cell malignancies, Autoimmune disease | Cell-based reporter assay with ELF2 lentivirus; PPI assays (AlphaScreen). |
| DNA-binding Inhibitor | Structure-based drug design groups | Lymphoma, Myeloma | DBD-specific constructs for EMSA/Fluorescence Polarization; purified ETS domain. |
| Gene Therapy / Cell Engineering | Translational research labs | Primary immunodeficiency | Stable overexpression lentivirus (high-titer) for functional rescue studies. |